Tirzepatide criteria: what you actually need to qualify

The myth that only very high BMIs qualify

The most common misconception our prescribers encounter is that tirzepatide is reserved for people with a BMI well above 35. It isn't. The licensed eligibility for Mounjaro in a private clinical setting follows the product's summary of characteristics: a BMI of 30 or above qualifies on its own, and a BMI of 27 or above qualifies when at least one weight-related condition is present. That lower threshold matters to a large group of people who fall between 27 and 30 and have been told, sometimes by a GP, that they are not heavy enough. Conditions that count include type 2 diabetes, prediabetes, hypertension, high cholesterol, obstructive sleep apnoea and osteoarthritis, among others.

The ethnic-background adjustment adds another layer many people miss. UK clinical guidance recognises that metabolic risk accumulates at lower BMI values in South Asian, Chinese, Middle Eastern, Black African and African-Caribbean populations, so thresholds are applied 2.5 kg/m² lower across the board. In practice that means a BMI of 27.5 can open the same door as 30 for many patients. The BMI requirements for Mounjaro page covers this in more detail if you want to work through your own numbers before a consultation.

One practical note: BMI is calculated from height and weight, and at nume (at nume) weight is verified on a live video call rather than taken on trust. That step protects you as much as it protects the clinical process; a prescriber making decisions from an inaccurate number is not making good decisions.

What a prescriber looks at beyond the BMI figure

Hitting the BMI threshold is necessary but not sufficient. A prescriber reviewing a tirzepatide consultation will also assess your current medicines (some combinations need careful thought) and your personal and family medical history. A history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 is a contraindication listed in the Mounjaro SmPC. Pancreatitis, certain gastrointestinal conditions and kidney function all come into the clinical picture.

Women of childbearing age are asked about contraception. Because tirzepatide slows gastric emptying, it can reduce absorption of oral contraceptive pills, particularly in the first four weeks of starting treatment and for four weeks after each dose increase. NHS guidance recommends adding a non-oral method during those windows. This is not a reason to be refused treatment; it is something your prescriber will discuss and document. The same guidance flags that anyone planning a pregnancy should stop tirzepatide and allow a wash-out period first.

If you are wondering whether tirzepatide is suitable for your specific situation, the honest answer is that suitability depends on the full conversation, not a checklist. A prescriber reads nuance that a self-assessment tool cannot.

NHS criteria versus private prescription: not the same thing

NICE recommended tirzepatide for NHS use in England in December 2024 (TA1026), but the NHS eligibility criteria are deliberately stricter and rolling out in phases. As of mid-2026, NHS access in England requires a BMI of 40 or above with four or more of a specific list of five conditions, or (in the second cohort activated in June 2026) a BMI of 35 to 39.9 with the same four conditions. Those thresholds are far higher than the licensed private criteria, and NHS waiting lists through specialist weight management services add further delay.

Private prescription follows the licensed product criteria, not the NICE implementation thresholds. That gap is why many people who are clinically appropriate for tirzepatide (and for whom it could make a meaningful difference) are not currently eligible on the NHS. The criteria for getting Mounjaro from a GP explains the NHS route in full, including what the phased rollout means for GP prescribing from April 2026. On cost, the Eli Lilly price increase page gives context on how private pricing has shifted since September 2025, which is useful background before you check your eligibility with our team.

NICE's appraisal of tirzepatide, TA1026, published by NICE in December 2024, is publicly available and sets out both the clinical evidence base and the NHS commissioning conditions if you want to read the primary document. For the licensed product's full list of contraindications and cautions, the Mounjaro SmPC on the electronic Medicines Compendium is the authoritative reference.

What happens after you confirm you meet the criteria

Confirming that you meet the criteria is step one. The consultation is step two, and at nume, it costs nothing. You fill in a structured clinical questionnaire; a GPhC-registered Independent Prescriber reviews it the same day. Not software. Not an automated triage. A named prescriber reads your answers and either approves treatment, requests more information or advises that treatment isn't appropriate. The identity and weight verification happens on video, which takes minutes.

Treatment starts at the 2.5 mg dose (that first pen's job is helping your body adjust gradually, not producing rapid weight loss) and titration is guided by your prescriber over subsequent months. The pen lives in the fridge between doses, and most people find tucking it in the fridge door next to everyday items becomes part of the weekly routine quickly enough. If your delivery timing ever shifts and you find yourself wondering whether you can take tirzepatide a day early, that page walks through what the clinical guidance actually says.

Every repeat order at nume is clinically re-reviewed before dispatch. That is not a formality; it is how prescribing should work for a medicine that changes dose over time. The full Mounjaro criteria page covers both private and NHS routes side by side if you want a broader comparison before deciding. When you're ready, the next step is straightforward: start your free consultation with our clinical team.